• DOI:10.1080/21678421.2016.1221971
• Corpus ID: 4584977

Phase I clinical trial of safety of L-serine for ALS patients

@article{Levine2017PhaseIC,
  title={Phase I clinical trial of safety of L-serine for ALS patients},
  author={Todd D. Levine and Robert G. Miller and Walter G Bradley and D. Moore and David S. Saperstein and Lynne E Flynn and Jonathan S. Katz and Dallas A. Forshew and James S Metcalf and Sandra Anne Banack and Paul Alan Cox},
  journal={Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration},
  year={2017},
  volume={18},
  pages={107 - 111}
}

• T. Levine, Robert G. Miller, +8 authors P. Cox
• Published 2 January 2017
• Medicine, Psychology
• Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Abstract We performed a randomized, double-blind phase I clinical trial for six months on the effects of oral L-serine in patients with ALS. The protocol called for enrollment of patients with a diagnosis of probable or definite ALS, age 18–85 years, disease duration of less than three years and forced vital capacity (FVC) ≥ 60%. Patients were randomly assigned to four different oral twice-daily dose regimens (0.5, 2.5, 7.5, or 15 g/dose). Blood, urine and CSF samples, ALS Functional Rating Scale-Revised (ALSFRS-R) scores and forced vital capacity (FVC) were obtained throughout the trial. Disease progression was compared with matched historical placebo controls from five previous ALS therapeutic trials. Of 20 patients enrolled, one withdrew before receiving study drug and two withdrew with gastro-intestinal problems. Three patients died during the trial. L-serine was generally well tolerated by the patients and L-serine did not appear to accelerate functional decline of patients as measured by slope of their ALSFRS-R scores. Based on this small study, L-serine appears to be generally safe for patients with ALS.